openPR Logo
Press release

HIV-associated Lipodystrophy Market Analysis, Segments, Growth and Value Chain 2017-2025

09-28-2017 06:10 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
HIV-associated Lipodystrophy Market Analysis, Segments,

Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities, including insulin resistance, and dyslipidemia. The HIV-associated lipodystrophy groups together different clinical conditions, which are lipoatrophy and lipoaccumulation. Lipoatrophy is associated with subcutaneous fat loss, whereas lipoaccumulation is the increase in visceral fat. In certain cases, HIV-associated lipodystrophy may occur as a combination of these two conditions; thus, its treatment and prevalence measurement are difficult.

Request Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22925
The global HIV-associated lipodystrophy market is witnessing unprecedented dynamics. Several research studies are directed toward finding out the link between the two mechanisms of lipodystrophy in such a way that a single mechanism will can occur for redistribution of fat. Improving healthcare infrastructure and increasing incidence rates of HIV/AIDS patients globally are expected to drive the growth of the global HIV-associated lipodystrophy market. However, lower adoption of therapeutic treatment and demand for constant nutritional supply from patients is anticipated to restrain the growth of the global HIV-associated lipodystrophy market.

The global HIV-associated lipodystrophy market has been segmented based on lipodystrophy type, therapeutic class, and distribution channels. On the basis of lipodystrophy type, the market has been classified into lipoatrophy and lipoaccumulation. In terms of therapeutic class, the market is divided into anabolism modulators, insulin resistance modulators, mitochondrial antioxidants (L-carnitine), and other miscellaneous metabolic agents. Anabolism modulators are further bifurcated into growth hormones and anabolic steroids. Insulin resistance modulators can be sub-segmented into metformins, thiazolidinediones, and others. Growth hormones are widely used for the treatment of HIV-associated lipodystrophy due to their efficacy. Based on distribution channels, the global HIV-associated lipodystrophy market is categorized into hospital pharmacy stores, retail pharmacy stores, and online pharmacies. Hospital pharmacy stores are expected to account for higher market share due to their ease of connectivity, and trend of utilization of newly advanced products among end-users including physicians and patients.

There is a lack of evidence-based strategies for the treatment of HIV-associated lipodystrophy. The treatment switch between the two lipodystrophy conditions, along with HIV drugs that possess lower mitochondrial toxicity, is an emerging trend in the global HIV-associated lipodystrophy market. There is a large patient pool in emerging countries, where lower drug affordability is a major challenge for market penetration of HIV-associated lipodystrophy therapeutics. Thus, the introduction of affordable drugs by local manufacturers serves as a major opportunity in the global HIV-associated lipodystrophy market. However, the other treatment options such as cosmetic surgeries also arrests the growth of the global HIV-associated lipodystrophy market.

On the basis of geography, the global HIV-associated lipodystrophy market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to grow at a high CAGR owing to factors like large patient pool, increasing demand for low cost drugs, rising awareness of the treatment options for HIV-associated lipodystrophy, and adoption of better healthcare facilities. North America is projected to dominate the global HIV-associated lipodystrophy market due to increasing adoption of new and technologically advanced products, high per capita health expenditure, and substantial investments in research and development for efficient treatment options.

Key players in the global HIV-associated lipodystrophy market are Novelion Therapeutics Inc., Theratechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc (Viiv Healthcare Group of Companies), AbbVie Inc., Bristol-Myers Squibb Company, and AstraZeneca plc, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request TOC of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22925

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV-associated Lipodystrophy Market Analysis, Segments, Growth and Value Chain 2017-2025 here

News-ID: 747011 • Views: 106

More Releases from Transparency Market Research

Wearable EEG Devices Market: Growing incidences of Neurovascular Disorders is Dr …
According to new market research titled 'Wearable EEG Devices Market to 2027 - Global Analysis and Forecasts by Channel and Application.' The global wearable EEG devices market is expected to reach US$ 1,556.35 Mn in 2027 from US$ 745.05 Mn in 2018. The market is projected to grow with a CAGR of 8.7% from 2019-2027. The report provides trends prevailing in the global wearable EEG devices market and the factors
Decentralized Electricity Generation Market - Global Industry Analysis, Share, G …
Global Decentralized Electricity Generation Market: Overview With the increasing installation of smart grids and the rising number of electricity generation resources, the power generation industry has been undergoing a significant change over the recent past. The modification in the grid structure, which permits decentralization of electricity generation, is acting as the main driving force behind the substantial growth of the global market for decentralized electricity generation. The main objective of this research
Global Sucralose Market Outlook In The Developed And Emerging Industry
Sucralose Market Overview Sugar substitute market is witnessing an increasing demand driven by the increasing sales of various sugar substitutes such as natural sweeteners and artificial sweeteners. Sucralose, an artificial sweetener used as a sugar substitute is highly preferred by consumers owing to its zero calorie attribute. Though sucralose is 600 times sweeter than sugar but interestingly it is not identified as the carbohydrate by the human body. Sucralose has its
Flavored Syrup Market - Growth Powered with Latest Development Scenario & Influe …
Flavored Syrup Market Introduction Global syrup market is witnessing a significant demand generated by the food and beverage industry. Consumers' increasing preference for different and personalized flavors in food has driven the syrup manufacturers to produce a wide range of flavored syrups. Flavored syrups contain artificial or natural flavorings mixed along with sugar and water. Obtain Report Details @ https://www.transparencymarketresearch.com/flavored-syrup-market.html Increasing demand of flavored syrups especially among the consumers contributes to the

All 5 Releases


More Releases for HIV

Global HIV Market to 2024
The HIV market was valued at $16bn in 2015 and is forecast to expand at a CAGR of 3.7% between 2015 and 2024, culminating in 2024 global sales of $23bn.The expected arrival of new classes of therapies could result in a paradigm shift in the treatment of HIV treatment. Globally, around 35 million people are infected with HIV. Approximately 3 million people in the U.S and 2.5 million in top 5
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Global HIV Infection Pipeline Analysis
The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have
Global HIV Therapeutics Market
The HIV Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral